Labiana |
27 May
Labiana, the pharmaceutical company specializing in both animal and human health and listed on BME Growth, returns this year to the MedCap Forum—the key event for European small and mid-cap investors listed in Spain—to present its business model and expansion plan to interested investors.
Labiana |
27 May
Labiana, the pharmaceutical laboratory specializing in both animal and human health and listed on BME Growth, will present its latest additions to its product portfolio at the ANEMBE International Congress of Bovine Medicine, taking place from May 28 to 30 in Vitoria. Among the highlights is a new antibiotic with zero milk withdrawal time in dairy cattle.
Labiana |
23 April
Labiana closed the 2024 fiscal year with revenues of €66.26 million, representing a 13.3% increase compared to the previous year.
Labiana |
25 March
Labiana, the pharmaceutical laboratory specialized in animal and human health listed on BME Growth, has added Lexylan, a new antibiotic classified as Category C in its prescription guidelines, to its product portfolio.
Labiana |
21 March
Labiana, the pharmaceutical laboratory specialized in both animal and human health listed on BME Growth, is expanding its business in the human health sector with the launch of a product line dedicated entirely to the well-being and care of women.
Labiana |
26 September
Labiana, el laboratorio farmacéutico especializado en salud animal y humana cotizado en el BME Growth, se posiciona como laboratorio experto en el análisis de flor del cannabis con fines terapéuticos, lo que permitirá a las compañías que se encargan de su distribución a nivel mundial, su liberación al mercado.
